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The efficacy of aprotinin to reduce intraoperative bleeding tendency in 
cardiac operations has been demonstrated in several studies. Aprotinin is 
a polybasic polypeptide and has antigenic properties. Anaphylactic reac- 
tions to aprotinin have been described. The aim of the present study was to 
evaluate the prevalence of adverse reactions to reexposure to high-dose 
aprotinin. The clinical outcome of all patients undergoing heart operations 
in our institution between 1988 and 1995 with at least two exposures to 
aprotinin was investigated. There were 248 reexposures toaprotinin in 240 
patients: 101 adult and 147 pediatric ases. The total aprotinin doses were 
4.9 x 106 (interquartile range 2 × 106) KIU (adults) and 1.3 x 106 
(interquartile range 1.2 x 106) KIU (pediatric patients). The time between 
the first and second aprotinin exposures was 344 (interquartile range 1039) 
days. Seven adverse reactions to aprotinin were found (2.8%). The severity 
of the reaction ranged from ild (no intervention) tosevere (longer-lasting 
circulatory depression despite vasopressor therapy). All patients urvived 
the event. Patients with an interval ess than 6 months since the previous 
exposure had a statistically higher incidence of adverse reactions than 
patients with a longer interval (5/111 or 4.5% vs 2/137 or 1.5%, p < 0.05). 
Two patients reacted to a test dose of 10,000 KIU aprotinin. Pretreatment 
with antihistaminics was done in 60% of the patients. We recommend the 
following procedure for reexposure with high-dose aprotinin: (1) delay of 
the first bolus injection of aprotinin until the surgeon is ready to begin 
cardiopulmonary b pass, (2) test dose of 10,000 KIU aprotinin in all 
patients with aprotinin treatment, (3) H1/H 2 blockade in known or possible 
reexposures, and (4) avoidance of reexposure within the first 6 months after 
the previous exposure to aprotinin. With these precautions a reexposure to
aprotinin in patients with a high risk of bleeding is justified, because the 
benefits of aprotinin treatment outweigh the relative risk of a serious 
allergic reaction. (J Thorac Cardiovasc Surg 1997;113:194-201) 
A Protinin is used in cardiac operations to reduce intraoperative and postoperative bleeding ten- 
dency. 1-5 It has been proved effective in this indica- 
tion. 6 Aprotinin, a polybasic polypeptide, is a natu- 
rally occurring inhibitor of proteolytic enzymes and 
consists of 58 amino acids. It has a molecular weight 
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of 6500 daltons and is derived from bovine lungs. As 
an allogeneic protein it possesses antigenic proper- 
fies and the possibility of an adverse reaction to the 
agent exists. Allergic reactions after reexposure to 
high-dose aprotinin have been described in case 
reports. 7-15 It has been shown that formation of 
immunoglobulin (Ig) G antibodies to aprotinin 
takes place in about 50% of all patients treated with 
aprotinin.16, 17 Because aprotinin has been used on a 
broad scale in Europe during the past 8 years in 
many cardiac centers, the number of patients ched- 
uled for a second cardiac operation after a primary 
exposure to aprotinin is increasing. Aprotinin is 
especially efficacious in cardiac reoperations 1' 18; 
however, the question remains whether the relative 
risk of an anaphylactic reaction might outweigh the 
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benefit of this drug if it is given to previously 
sensitized patients. 
The present study was done to evaluate the 
prevalence of adverse reactions after reexposure to 
aprotinin and to develop guidelines to reduce the 
risk and sequelae of such a reaction. 
Methods 
With institutional approval the charts of patients who 
underwent a cardiac reoperation between January 1988 
and March 1995 were retrospectively analyzed. Adult and 
pediatric patients who had cardiac operations with the use 
of the heart-lung machine were included. Patients up to 
age 18 years were considered as pediatric patients. All 
reexposures were registered; thus cases in which patients 
had a third exposure to aprotinin within the study period 
were counted as two reexposures. Data of patients with at 
least two exposures to aprotinin were entered into the 
study and were reviewed independently by two investiga- 
tors (W.D., A.E.). An allergic reaction was assumed if at 
least one of the following symptoms was present within 10 
minutes after aprotinin administration: (1) a decrease of 
systolic blood pressure greater than 20% from the base- 
line value, (2) a change of heart rate greater than 20% 
from the baseline value, (3) an increase of inspiratory 
pressure greater than 5 cm H20, and (4) a skin reaction. 
Anesthesia was done with a standard intravenous tech- 
nique with either fentanyl or sufentanil, midazolam, and 
pancuronium for muscle relaxation. A bubble oxygenator 
was used in almost all patients. Priming for adult patients 
consisted of 1400 ml crystalloid solution. Myocardial 
preservation was achieved by infusion of 1000 ml cold 
crystalloid cardioplegic solution (Bretschneider HTG, F. 
Köhler Chemie, Alsbach, Germany). Cardiopulmonary 
bypass (CPB) was done with moderate hypothermia of 30 ° 
to 32 ° C rectal temperature and a flow rate of 2.4 L/min 1/ 
m -2. Priming of the oxygenator for the pediatric patients 
was done according to the body weight with crystalloids or 
blood. Pediatric CPB was done with hypothermia of 26 ° to 
28°C rectal temperature and a ftow rate of 1.2 to 2.4 
L/min-1/m 2 or with deep hypothermia (20°C rectal 
temperature) and circulatory arrest. Anticoagulation for 
CPB was done with porcine mucosa heparin, 375 U/kg. 
Anticoagulation was controlled with the celite activated 
clotting time. 
Aprotinin dosage was as follows. A test dose of 10,000 
KIU aprotinin was given 10 minutes before the first bolus. 
Adult patients received an initial bolus of 2 × 106 KIU 
aprotinin with the start of operation followed by a contin- 
uous infusion of 5 × 10 » KIU/hr. Additionally, 2 × 106 
KIU was added to the pump prime. Pediatric patients 
received a bolus of aprotinin, 30,000 KIU/kg, after induc- 
tion of anesthesia nd the same dose was added to the 
pump prime. The dosage regimen changed during the 
study period insofar as the first aprotinin dose was delayed 
until the surgeon was ready to cannulate the aorta and 
begin CPB immediately in case of a severe adverse 
reaction. 
Reactions to aprotinin were classified as mild (no 
intervention), moderate (restoration of circulation within 
Table I. Type of operations 
Adults Children 
CABG 20 0 
Valve rereplacement 63 18 
Conduit or shunt (with CPB) 4 44 
HTX 3 0 
Correction of congenital defects 10 84 
Miscellaneous 1 1 
Total 101 147 
CABG, Coronary artery bypass grafting; HTX, heart ransplantation. 
15 minutes after the event by the use of vasopressors), or
severe (longer-lasting circulatory depression and instabil- 
ity despite vasopressor therapy). These reactions were 
registered regardless of surgical manipulations on the 
heart or the great vessels. The regimen of prophylactic 
antihistaminic blockade was changed during the study 
period: during the first years Ha/H2 blockade (clemastine 
0.03 mg/kg, cimetidine 5 mg/kg) was given at the discre- 
tion of the anesthesiologist; since January 1993 H1/H2 
blockade was given to all patients with a reexposure to 
aprotinin. Additionally, almost all pediatric patients were 
treated with dexamethasone (1 mg/kg). 
Parametric data are reported as median and interquar- 
tile range (IQR). Differences in patient demographics 
were determined by Student's t test for continuous vari- 
ables and X 2 or Fisher's exact test for dichotomous 
variables with p < 0.05 as significant (Systat 5.2 for the 
Macintosh computer, Systat, Evanston, Ill.). 
Results 
More than 6000 patients undergoing heart oper- 
ations were treated with high-dose aprotinin within 
the study period in this institution. Among these 
there were 248 reexposures to aprotinin in 240 
patients in 101 operations on adult patients and 147 
operations on pediatric patients. The ages of the 
patients were 59.5 ( IQR 16.2) years (adult patients) 
and 5.2 (2.4) years (pediatric patients), and the body 
weights were 67 ( IQR 12.5) kg (adult patients) and 
10.2 (12.5) kg (pediatric patients). The time between 
the first and the second aprotinin exposures was 344 
( IQR 1039) days. The types ,of operations done are 
given in Table I. The total aprotinin doses were 
4.9 × 106 ( IQR2 × 106) K IU  (adults) and 1.3 × 106 
(1.2 × 106) K IU  (pediatric patients). Antihistaminic 
pretreatment  with H1/H 2 blockers was done in 141 
patients, t reatment with corticosteroids in 140 pa- 
tients, and combined treatment with both these 
agents in 83 patients. 
Seven adverse reactions to aprotinin were found 
(Tables I I  and I I I) ,  of which one was unclear and 
classified as a "doubtful" reaction to aprotinin (pa- 
tient 1). The course of these patients is described in 
the following section. Two patients reacted to the 
1 9 6 Dietrich et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
January 1997 
Table II. Distribution and severity of adverse 
reactions to aprotinin 
Reactions 
n Doubtful Mild Moderate Severe Total 
Adult 101 1 2 1 4 
Pediatric 147 1 2 3 
Total 248 1 1 1 3 7 
Explanation of severity score is given in the text. 
test dose of 10,000 KIU aprotinin (1 mild, 1 severe; 
patients 6 and 7) and received no additional apro- 
tinin. In 137 patients the time to the previous 
aprotinin exposure was longer than 200 days. Two 
patients in this group reacted to aprotinin (1.5%). 
On the other hand, 5 (4.5%) of 111 patients with an 
interval ess than 200 days reacted to aprotinin (p < 
0.05) (Fig. 1). All patients with reactions urvived 
the event; one of these patients died of multiorgan 
failure on postoperative day 6 as a result of the 
underlying disease. Mortality (30 days) of all pa- 
tients was 4.8%. 
Case reports 
Patient 1. This 71-year-old woman had coronary 
artery disease and aortic regurgitation. She had had 
a previous aortic and mitral valve replacement and 
triple coronary artery bypass grafting 193 days be- 
fore undergoing the operation in which the reaction 
to aprotinin occurred. At this most recent operation 
she had stable angina caused by an occluded vein 
graft to the left anterior descending artery and 
paravalvular leakage around the prosthetic aortic 
valve. During the first operation she had been 
treated with 6 × 10 ° KIU aprotinin. At the second 
operation anesthesia was induced with fentanyl and 
flunitrazepam. The patient received H1/H 2 blockade 
(clemastine 0.03 mg/kg, cimetidine 5 mg/kg) after 
induction of anesthesia. Ten minutes later and 
before skin incision aprotinin infusion was started. 
After 5 × 105 KIU aprotinin was administered the 
blood pressure dropped from 140/40 to 100/40 mm 
Hg and the aprotinin infusion was stopped. Blood 
pressure returned to normal with 15/xg norepineph- 
rine administered intravenously within 5 minutes. At 
this time it was unclear whether the hemodynamic 
changes were caused by aprotinin. Therefore the 
aprotinin infusion was started again. Systolic blood 
pressure varied between 140 and 120 mm Hg. 
Another bolus of 5 × 10 s KIU aprotinin coincided 
with surgical manipulation of the heart and ventric- 
ular fibrillation occurred. After electric defibrilla- 
tion the hemodynamic condition was stable, but 
aprotinin administration was stopped and tranex- 
amic acid in a total dose of 4 gm was given instead. 
During CPB the aortic valve was reinforced with 
sutures and the left anterior descending artery was 
supplied by the left thoracic artery. After termi- 
nation of CPB increased bleeding tendency was 
evident, but the patient's condition was hemody- 
namically stable with a 5 /xg/kg-1/min 1 dopamine 
infusion. The postoperative course was complicated 
by increased chest ube drainage, which necessitated 
reexploration for surgical hemostasis 6 hours after 
operation. The patient recovered uneventfully. Be- 
cause of the coincidence of hemodynamic instability 
with surgical manipulation and the uncertain rela- 
tion to aprotinin infusion this case was classified as 
a doubtful reaction to aprotinin. 
Patient 2. This 82-year-old female patient had 
mitral insufficiency. Operation for mitral valve re- 
pair during which she had received 5.5 × 106 KIU 
aprotinin had been done 127 days before the most 
recent operation. Because mitral regurgitation re- 
sumed shortly after the first operation a second 
operation was mandatory. Before operation the 
patient had dyspnea t rest and pulmonary conges- 
tion. After induction of anesthesia with sufentanil 
and midazolam she received H1/H 2 blockade. Dur- 
ing skin incision aprotinin infusion was started. 
After 5 × 10 » KIU aprotinin was administered the 
systolic blood pressure dropped from 90 to 50 mm 
Hg but was restored within 5 minutes with 50 /xg 
norepinephrine administered intravenously. Aproti- 
nin infusion was stopped. Corticosteroids (500 mg 
methylprednisolone) were given. Because of difficult 
preparation it took 90 minutes until the start of 
CPB. During this time the systolic blood pressure 
was stable between 90 and 70 mm Hg with inotropic 
support of 5 /xg/kg-1/min -1 dopamine. During a 
CPB time of 59 minutes mitral regurgitation was 
corrected. After termination of CPB the patient's 
circulatory condition was unstable despite inotropic 
support. After operation, prolonged artificial venti- 
lation and hemodialysis were necessary. The patient 
died 6 days after operation of multiorgan failure. 
The contribution of the reaction to aprotinin to the 
fatal outcome remains unclear. This case was clas- 
sified as severe reaction to aprotinin. 
Patient 3. This 5-year-old female patient (body 
weight 18 kg) had a double-outlet right ventricle 
with hypoplastic left ventricle and a common atrio- 
ventricular valve. Five years before the most recent 
operation she had undergone resection of the right 
outflow tract without aprotinin therapy. Twenty- 
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Fig. 1. Graph shows interval between most recent and prior aprotinin treatments. Cases with reactions are 
marked with large dots. Five of seven reactions occurred within 200 days after previous exposure. See text 
for explanation of severity score. 
Table III. Data of patients with adverse reactions 
Pt. Age Time to most Test H1/H 2 
No. (y r )  Diagnosis Operation recent exposure doses blockers* Corticosteroids* Reaction 
1 71 Aortic regurgitation Valve replacement 193 days No Yes No Doubtful 
2 82 Mitral insufficiency Valve replacement 127 days No Yes No Severe 
3 5 DORV Cavopulmonary anastomosis 29 days No Yes Yes Moderate 
4 13 PA RV-PA conduit 1106 days Yes No No Severe 
5 20 TOF RV-PA conduit 19 yr Yes No No Mild 
6 66 Mitral insutficiency Valve replacement 120 days Yest Yes No Mild 
7 7 PA Aortopulmonary shunt 22 days Yest Yes No Severe 
DORV, Double-outlet right ventricle; PA, pulmonary atresia; RV-PA, right ventricle-pulmonary artery; TOF, tetralogy of Fallot. 
*Given before the test dose of aprotinin. 
tReaction to test dose. 
nine days before the most recent operation a cavo- 
pulmonary anastomosis was done. During that op- 
eration she was treated with 9 × 105 KIU aprotinin. 
Because the flow to the lungs was not satisfactory a 
revision of the cavopulmonary anastomosis was nec- 
essary. After induction of anesthesia with fentanyl 
and flunitrazepam 250 mg methylprednisolone and 
H1/H 2 blockers were given. During skin incision 
40,000 KIU aprotinin was infused. Five minutes 
later the systolic blood pressure dropped from 120 
to 80 mm Hg and the heart rate increased from 100 
to 150 min -1. There was no visible skin reaction. 
Aprotinin infusion was stopped. Blood pressure 
recovered within 10 minutes with 5/xg epinephrine 
administered intravenously. CPB was begun 70 min- 
utes later. No more aprotinin was given and the 
further course of operation was uneventful. This 
case was classified as moderate reaction to aproti- 
nin. 
Patient 4. This 13-year-old female patient had 
pulmonary atresia. Three years before the operation 
in which reaction to aprotinin occurred a right 
ventricle-pulmonary artery conduit had been 
placed. During that operation she had received 
1.4 × 106 KIU aprotinin. Most recently the patient 
underwent replacement of the calcified conduit. 
After induction of anesthesia with fentanyl and 
flunitrazepam 6 mg dexamethasone was given. Be- 
lore skin incision the patient received 50,000 KIU 
aprotinin as a test dose without adverse reaction. 
Ten minutes later infusion of 1.3 × 106 KIU apro- 
tinin over 10 minutes was begun. Five minutes later 
the systolic blood pressure dropped from 110 to 60 
mm Hg. Despite massive inotropic support the 
mean arterial pressure remained between 30 and 40 
mm Hg. Operation was started immediately and 
commencement of CPB was possible after 45 min- 
utes of preparation. The patient was cooled to a 
core temperature of 16.9°C and the conduit re- 
placement was done with the use of deep hypother- 
mic circulatory arrest lasting 57 minutes. Total CPB 
time was 153 minutes. After termination of CPB 
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circulation recovered slowly with inotropic support 
of 7.5/~g/kg-1/min -1 dopamine. The postoperative 
course was uneventful. This case was classified as 
severe reaction to aprotinin. 
Patient 5. This female patient was operated on 19 
years previously for correction of tetralogy of Fallot. 
There was no information available about aprotinin 
therapy during that operation; however, itwas usual 
at that time to treat patients in the postoperative 
period with small doses (1 to 5 × 10 » KIU) of 
aprotinin. The most recent operation was scheduled 
for closure of a residual ventricular septal defect and 
for placement of a right ventricle-pulmonary tery 
conduit. Anesthesia was induced with fentanyl and 
flunitrazepam, and the patient received a test dose 
of 10,000 KIU aprotinin, which was tolerated with- 
out adverse reactions. After sternotomy an infusion 
of aprotinin was started. When 1.5 × 106 KIU 
aprotinin had been infused a slight drop in blood 
pressure was noted. Shortly after, flush and wheals 
on the forehead were seen. Peripheral arterial oxy- 
gen saturation dropped from 95% to 85%. Systolic 
blood pressure decreased from 100 to 80 mm Hg but 
recovered spontaneously within a few minutes. Cor- 
ticosteroids (250 mg) and HJH 2 blockers were given 
at this time. To reduce a suspected right-to-left 
shunt norepinephrine (10 txg) was given 30 minutes 
after the event and oxygen saturation recovered to 
93%. Aprotinin infusion was stopped. The oxygen- 
ator had already been primed with 2 × 106 KIU 
aprotinin. Thus the oxygenator had to be replaced 
and filled with an aprotinin-free prime. Circulation 
remained stable and the operation was done un- 
evenffully without further sequelae. This case was 
classified as mild reaction to aprotinin. 
Patient 6. This 66-year-old patient had mitral 
regurgitation. He had had a previous mitral valve 
replacement 120 days before undergoing the oper- 
ation in which a reaction to aprotinin occurred. The 
most recent operation was done for repair of a 
leakage on the mitral valve and aortic valve replace- 
ment o correct aortic valve insufficiency. During the 
previous uneventful operation he had received 6 × 
106 KIU aprotinin. In the most recent operation, 
after standard induction of anesthesia with sufen- 
tanil and midazolam H1/H 2 blockade was done. 
During skin incision a test dose of 10,000 KIU 
aprotinin was given. Shortly after, a skin flush 
developed, but the patient's condition remained 
hemodynamically stable. No further aprotinin was 
given and the operation was continued routinely. 
Perfusion pressure during CPB was remarkably ow. 
This case was classified as mild reaction to aprotinin. 
Patient 7. This 7-year-old boy with a body weight 
of 19 kg had pulmonary atresia and ventricular 
septal defect. Other complex lesions rendered pri- 
mary correction of the defect impossible. In his first 
year of life an aortopulmonary shunt was placed. 
The shunt was renewed 4 years before the most 
recent operation. During that operation the patient 
received a total of 80,000 KIU aprotinin. In a third 
operation 3 weeks before the most recent operation 
a replacement of the aortopulmonary shunt was 
done. During this operation 1.5 × 106 KIU aproti- 
nin was given after injection of H1/H 2 blockade and 
8 mg dexamethasone. The patient tolerated this 
reexposure to aprotinin without sequelae. Oxygen 
saturation remained poor after operation. There- 
fore a new shunt revision was scheduled 3 weeks 
later. HJH2 blockade was given before this most 
recent operation. Thirty minutes after the start of 
the operation a test dose of 10,000 KIU aprotinin 
was injected. Immediately the systolic blood pres- 
sure dropped from 100 to 70 mm Hg. The heart rate 
increased from 100 to 180 min -1. Venous cannula- 
tion for CPB was difficult because of severe bleeding 
from the site of cannulation. Despite 50/xg epineph- 
rine the blood pressure remained 80/40 mm Hg. 
Blood loss at this time was severe. CPB was begun 
20 minutes after aprotinin injection. After termina- 
tion of CPB inotropic support with norepinephrine 
and dopamine was required. The postoperative p - 
riod was uneventful. This incident was classified as 
severe reaction to aprotinin. 
Discussion 
The present investigation is a retrospective study. 
However, our data collection is extensive and com- 
plete since 1988. Additionally, because we are aware 
of the possibility of an adverse reaction to aproti- 
nin 19 the reports about hese reactions are carefully 
collected. Accordingly, the data are accurate and 
this report completely describes our experience with 
aprotinin reexposures during the past 7 years. We 
use aprotinin only in patients undergoing CPB. 
Because we have noted beneficial effects of aproti- 
nin in pediatric heart operations, 2° the percentage 
of pediatric patients in our study is high. The 
prevalence of adverse drug reactions to aprotinin 
reexposure was 7 (2.8%) of 248. This number differs 
from those of other reports: Schulze and associ- 
ates 12 reported a prevalence of 5.8% for allergic 
reactions after aprotinin reexposure, Diefenbach 
and associates 1° a frequency of 6%, and Ceriana nd 
colleagues s 1 patient in 200 reexposures. This dif- 
ference may be explained by incomplete data col- 
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lection either because of missed reexposures with- 
out sequelae or overlooked mild reactions to 
aprotinin. Of note, in our patients there was a wide 
variation in the severity of the symptoms of the 
adverse vents and it was not always unequivocally 
possible to relate hemodynamic instability to a re- 
action to aprotinin. 
As a protein aprotinin has antigenic properties. 21
Aprotinin has similarities to protamine: both have 
nearly identical molecular weights, are isolated from 
animal sources, and have been implicated in produc- 
ing anaphylactic reactions. 22 Anaphylactic reactions 
have been described since the clinical use of this 
drug. 23 Weipert and colleagues 17demonstrated that 
in 50% of patients with high-dose aprotinin treat- 
ment IgG antibodies to aprotinin develop within 3 
months after operation. After 48 months 50% of all 
patients still showed measurable levels of IgG 
against aprotinin. These results have been con- 
firmed by others, ló The formation of IgE antibodies 
against aprotinin, which are responsible for the 
immediate-type allergic reaction, has also been de- 
scribed.9, a0 If the reactions to aprotinin are antibody 
mediated, the assessment of drug-specific antibodies 
before treatment may identify patients at risk. How- 
ever, a clinically useful, reliable, and predictive test 
system does not yet exist. 
Skin testing, either by prick or intradermal test, is 
an established method to identify patients hypersen- 
sitive to histamine-releasing drugs such as penicil- 
lin 24 and streptokinase. 25 However, in our experi- 
ence, results of prick tests with pure, undiluted 
aprotinin before operation were not encouraging as 
they were in other centers. 16 In our hands, results 
were false-negative in three patients with intraoper- 
ative reaction to aprotinin; none of our prick test 
results was positive so rar. On the other hand, 
Dewachter and coworkers 9 reported a positive in- 
tradermal reaction 6weeks after an adverse reaction 
to aprotinin. 
The use of prophylactic antianaphylactic medica- 
tion and the timing of aprotinin administration 
changed over the years in our institution: H JH  2 
blockade (clemastine 0.03 mg/kg, cimetidine 5 mg/ 
kg) is now used in all patients with a reexposure to 
aprotinin. The rationale for this treatment is based 
on the fact that histamine mediates anaphylactic 
reactions. 26 Lorenz and colleagues 27demonstrated 
that the prophylactic use of H1/H 2 antagonists re- 
duced histamine-related disturbances in patients 
treated with gelatine infusion from 26% in the 
control group to 2% in the group treated with H1/H 2 
antagonists. The potential impact of H JH  2 blockade 
has also been demonstrated in anaphylactoid reac- 
tions to radiographic ontrast media. 28 Six of our 
seven patients with adverse reactions received 
H JH  2 blockers. We can only speculate whether this 
treatment attenuated or blunted the reaction to 
aprotinin, but it is remarkable that the prevalence 
and severity of the events in our study were less 
pronounced than those described in other case 
reports.8, 10, 12 Aprotinin, like other polypeptides, 
has been implicated as a histamine releaser from 
mast cells. 21 Thus it seems to be prudent o redvce 
histamine liberation before the treatment. 27' 29 In 
cases of aprotinin reexposure, H JH  2 blockade, 
though not yet proved in a controlled study to be 
effective, is recommended. The role of pharmaco- 
logic prophylaxis with corticosteroids i not yet 
established. 
TWo of our patients reacted after the test dose of 
10,000 KIU aprotinin. One of these reactions was 
mild (patient 6) and the other one was severe but 
coincided with severe surgical bleeding (patient 7). 
We strongly recommend an aprotinin test dose be 
administered before the loading dose. It is advisable 
to prime the heart-lung machine with aprotinin only 
after the test dose is given because otherwise in case 
of a reaction to the test dose an exchange of the 
oxygenator will be mandatory (patient 5). A test 
dose should also be given before CPB if only the 
oxygenator is primed with aprotinin ("low-dose reg- 
imen"), because an anaphylactic reaction also may 
occur during CPB. 
We delayed the test and the loading doses of 
aprotinin until the surgeon was ready to immedi- 
ately begin CPB. Hemostatic activation during the 
time before CPB is not comparable to the activation 
that occurs during CPB, 3° and the influence of 
aprotinin in this period, if any, is minimal. On the 
other hand, CPB may be lifesaving in face of a 
circulatory breakdown caused by anaphylaxis. Espe- 
cially in repeat operations the interval between skin 
incision and the start of CPB can be prolonged 
because of difficult preparation. Patients 2 and 4 had 
longer-lasting circulatory suppression after the ad- 
verse event because immedJiate commencement of 
CPB was not feasible. Some of the severe reactions 
to aprotinin reported in the literature occurred 
when the drug was given before skin incision or 
without a test dose. 7' 10, 12 
A remarkable time-dependent risk of anaphylac- 
tic reactions exists. The prevalence of reactions was 
higher in patients with a reexposure interval less 
than 200 days (4.5% vs 1.5% in patients with a 
longer drug-free interval, p < 0.05). In this period 
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aprotinin reexposure should be avoided and, if it 
seems to be unavoidable, taust be done with all 
precautions. The majority of case reports of adverse 
events describe a short interval of 35 days to 2 
months between the first and second aprotinin ex- 
posures. Patient 7 provides an example of this time 
dependency: his first reexposure after 4 years was 
uneventful, but during the second reexposure 21 
days later even the test dose caused severe hemody- 
namic instability. 
It is unknown yet whether a dose dependency of 
the adverse reaction exists. However, it is conceiv- 
able that every contact with the drug regardless of 
the dose is antigenic. Of  note, some fibrin glue 
preparations used outside North America contain 
aprotinin, which may also cause sensitization to 
aprotinin, 31 whereas the preparations of fibrin glue 
within North America are being formulated without 
either aprotinin or e-aminocaproic acid. 32 
In conclusion, the prevalence of adverse reactions 
to aprotinin during reexposures in the present study 
was 7 (2.8%) of 248. A reliable test system to 
identify patients at risk does not yet exist. We 
recommend the following procedure to reduce the 
risk and severity of adverse reactions to aprotinin: 
(1) delay of first bolus injection of aprotinin until the 
surgeon is ready to begin CPB, (2) test dose of 
10,000 K IU  aprotinin in all patients with aprotinin 
treatment (not restricted to reexposures), (3) H JH  2 
blockade in known or possible reexposures, and (4) 
avoidance of reexposure within the first 6 months 
after the last exposure. With these precautions a 
reexposure to aprotinin in patients with a high risk 
of bleeding is justified, and the benefits of aprotinin 
treatment outweigh the relative risk of a serious 
allergic reaction. 
Addendum 
Since the end of the study period in March 1995, an 
additional 134 patients underwent aprotinin reexposure in
our institution (45 adults and 89 pediatric cardiac pa- 
tients). One severe adverse vent occurred (19 days after 
sensitization). Thus until October 1996 we have had 382 
reexposures with eight adverse reactions to aprotinin (i.e., 
an incidence of 2.1%). 
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